Pfizer’s Xeljanz Squeezes Into ACR Treatment Guidelines For First Time
Executive Summary
For established RA, oral JAK inhibitor Xeljanz is on par with TNF blockers after DMARDs, American College of Rheumatology says, but for early RA, tofacitinib takes a back seat to biologics.